In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis-Reference-Cited by-同舟云学术

In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Published:2017-04 Issue:4 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Grohs Patrick¹,Taieb Gary¹,Morand Philippe²³,Kaibi Iheb¹,Podglajen Isabelle¹³,Lavollay Marie¹³⁴,Mainardi Jean-Luc¹³⁴,Compain Fabrice¹³⁴

Affiliation:

1. Service de Microbiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France

2. Service de Bactériologie, Assistance Publique-Hôpitaux de Paris, GH Cochin-Hôtel Dieu-Broca, Paris, France

3. Université Paris Descartes, Sorbonne Paris Cité, France

4. INSERM, UMR S 1138, Centre de Recherche des Cordeliers, Equipe 12, Paris, France

Abstract

ABSTRACT Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa , 11 Achromobacter xylosoxydans , and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia . In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02688-16

Reference21 articles.

1. Microbiology of Sputum from Patients at Cystic Fibrosis Centers in the United States

2. Lung Infections Associated with Cystic Fibrosis

3. Cystic Fibrosis Pulmonary Guidelines

4. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

5. Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis;Annals of Clinical Microbiology and Antimicrobials;2024-03-19

2. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia;Pathology;2023-08

3. In Vitro Susceptibility of Achromobacter Species Isolated from Cystic Fibrosis Patients: a 6-Year Survey;Antimicrobial Agents and Chemotherapy;2023-07-18

4. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β‐lactamase inhibitor combination;APMIS;2023-06-09

5. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis;Frontiers in Medicine;2023-05-05